Q1 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
Key Points
- Inhibikase Therapeutics Inc (IKT) is making rapid progress in the enrollment of its Phase two trial for Parkinson's disease, with expectations to enroll the final patient in June and report top-line data in the second half of the year.
- The company had positive interactions with FDA divisions, advancing regulatory discussions for its IKCO and Pro programs, potentially positioning these assets for opportunities in pulmonary arterial hypertension and blood and stomach cancers.
- Inhibikase Therapeutics Inc (IKT) has developed a novel antibody against a key marker of alpha-synuclein pathology in Parkinson's disease, which could enhance the tracking of disease pathology and treatment efficacy.
- The company held a productive pre-NDA meeting with the FDA, which provided a clear roadmap for NDA submission for its IKTO and Pro programs, potentially expanding the treatment's indications.
- Inhibikase Therapeutics Inc (IKT) has sufficient cash to fund operations through November 2024, providing stability for ongoing projects and research.
- Inhibikase Therapeutics Inc (IKT) reported a net loss of $4.6 million for the quarter, indicating ongoing financial challenges despite slight improvements from the previous year.
- There were 25 mild and three moderate adverse events observed in the ongoing trial, which might raise concerns about the treatment's safety profile.
- Four participants withdrew from the trial without completing the 12-week period, potentially impacting the study's outcomes and data integrity.
- The company is still working to find the necessary capital to initiate a two one-year extension trial, indicating potential financial constraints on future research phases.
- Inhibikase Therapeutics Inc (IKT) is in the early stages of seeking partners for its drug development, which is crucial for funding and successful trial continuation but has not yet secured any agreements.
Greetings, and welcome to Inhibikase Therapeutics' First Quarter 2024 financial results conference call. (Operator Instructions) As a reminder, this conference is being recorded and it is now my pleasure to introduce your host, Mr. Alexander Lobo, Stern Investor Relations. Thank you, Mr. Lobo, you may begin.
Good morning, and welcome to inhibitors Therapeutics First Quarter 2024 financial results conference call and audio webcast. With me today is Dr. Milton Werner, Chief Executive Officer, and Garth Lees-Rolfe, Chief Financial Officer. On May 15th, Inhibikase issued a press release announcing financial results for the first quarter ended March 31st, 2024. We encourage everyone to read yesterday's press release as well as in heavy cases, quarterly report on Form 10-Q, which has been filed with the SEC.
The company's press release and Form 10-Q are also available on Inhibikase website. In addition, this conference call is being webcast through the Investor Relations section of the company's website and will
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
